Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer

We retrospectively investigated in women treated with fulvestrant for HR+/HER2 negative advanced breast cancer clinical, pathological and molecular features associated with long-term benefit from treatment defined as being progression-free at 18 months. Specifically, we analyzed on formalin-fixed pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Torrisi, Rosalba, Vaira, Valentina, Giordano, Laura, Destro, Annarita, Basilico, Vera, Mazzara, Saveria, Salvini, Piermario, Gaudioso, Gabriella, Fernandes, Bethania, Rudini, Noemi, Masci, Giovanna, Santoro, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329443/
https://www.ncbi.nlm.nih.gov/pubmed/35896637
http://dx.doi.org/10.1038/s41598-022-16409-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329443/
https://www.ncbi.nlm.nih.gov/pubmed/35896637
http://dx.doi.org/10.1038/s41598-022-16409-7

Ejemplares similares